Intuniv Related Published Studies
Well-designed clinical trials related to Intuniv (Guanfacine)
Efficacy of guanfacine extended release assessed during the morning, afternoon,
and evening using a modified Conners' Parent Rating Scale-revised: Short Form. [2014]
Randomized, double-blind trial of guanfacine extended release in children with
attention-deficit/hyperactivity disorder: morning or evening administration. [2013]
Naltrexone with or without guanfacine for preventing relapse to opiate addiction
in St.-Petersburg, Russia. [2013]
Guanfacine extended-release: in attention deficit hyperactivity disorder. [2010.09.10]
Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. [2010.09.01]
Guanfacine extended-release: in attention deficit hyperactivity disorder. [2010]
Effects of extended-release guanfacine on ADHD symptoms and sedation-related
adverse events in children with ADHD. [2010]
Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. [2009.02]
A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. [2008.01]
A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. [2008]
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. [2007.09]
The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. [2007.05.15]
A phase i, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. [2007.04]
Well-designed clinical trials possibly related to Intuniv (Guanfacine)
Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in
children with comorbid tic disorders. [2011]
Pharmacotherapeutics of Tourette syndrome and stereotypies in autism. [2010.12]
Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. [2010.11]
Other research related to Intuniv (Guanfacine)
Sex differences in guanfacine effects on drug craving and stress arousal in
cocaine-dependent individuals. [2014]
A HPLC-MS method to detect and quantify guanfacine in urine. [2011.11.24]
Dried blood spots as a sampling technique for the quantitative determination of guanfacine in clinical studies. [2011.11]
Attention deficits following ADEM ameliorated by guanfacine. [2011.06]
Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. [2011.04]
Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain
injury: altered working memory and BOLD response. [2011]
Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD). [2010.10]
Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents. [2010.05]
Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD. [2010.03]
Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity. [2010.02]
Guanfacine overdose resulting in initial hypertension and subsequent delayed, persistent orthostatic hypotension. [2010.02]
Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. [2009.10]
Guanfacine potentiates the activation of prefrontal cortex evoked by warning signals. [2009.08.15]
Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. [2009.06]
Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. [2008.12]
The effects of guanfacine on working memory performance in patients with localization-related epilepsy and healthy controls. [2008.09]
Guanfacine in children with autism and/or intellectual disabilities. [2008.08]
Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. [2007.09]
Guanfacine and guanfacine extended release: treatment for ADHD and related disorders. [2007.01]
Other possibly related research studies
Changes in Emotions Related to Medication Used to Treat ADHD. Part I: A Literature Review. [2010.09.28]
Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006. [2010.02]
Cognitive enhancement as a pharmacotherapy target for stimulant addiction. [2010.01]
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. [2010]
Association between attention-deficit/hyperactivity disorder and epilepsy in pediatric populations. [2009.12]
Mapping the central effects of methylphenidate in the rat using pharmacological MRI BOLD contrast. [2009.12]
Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. [2009]
Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. [2009]
Carbamazepine-induced hyperammonemia. [2009.08.15]
Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. [2009.09]
Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. [2009.10]
Attention-deficit-hyperactivity disorder: an update. [2009.06]
Neuroleptic malignant syndrome secondary to quetiapine. [2009.04]
Dopamine vs noradrenaline: inverted-U effects and ADHD theories. [2009.02]
Changes and challenges: managing ADHD in a fast-paced world. [2007.11]
Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. [2008.02]
alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. [2007.08]
Centrally acting antihypertensive agents: an update. [2007.05]
Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches. [2007.03]
Differential noradrenergic influence on seizure expression in genetically Fast and Slow kindling rat strains during massed trial stimulation of the amygdala. [2007.02]
Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists. [2010.12]
Endothelin antagonism in patients with resistant hypertension and hypertension nephropathy. [2011]
Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists. [2011.07.15]
Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge. [2011.07.01]
Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. [2011.06.15]
Cognitive enhancers for the treatment of ADHD. [2011.08]
Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. [2011.04.13]
Catecholamine influences on dorsolateral prefrontal cortical networks. [2011.06.15]
Comparison of SHR, WKY and Wistar rats in different behavioural animal models: effect of dopamine D1 and alpha2 agonists. [2011.03]
Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. [2011.02]
The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. [2010.10]
Changes in emotions related to medication used to treat ADHD. Part I: literature review. [2011.02]
The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder. [2010.09]
Attention-deficit/Hyperactivity Disorder in the context of Autism spectrum disorders. [2010.10]
Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit
hyperactivity disorder. [2012]
Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents. [2012]
Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. [2011]
Pharmacotherapeutics of Tourette syndrome and stereotypies in autism. [2010]
Alpha2-adrenergic agonists for the management of opioid withdrawal. [2014]
Pharmacological treatment of comorbid PTSD and substance use disorder: recent
progress. [2014]
|
